University of Massachusetts

University of California

Massachusetts Institute of Technology

The Charles Stark Draper Laboratory, Inc.

Robert W Finberg

Evelyn A Kurt-Jones

Shenghua Zhou

Zachary Shriver

Ram Sasisekharan

Karthik Viswanathan

James Constantine Comolli

Jose Trevejo

Deborah Fygenson

Jennifer Wang

Ashok Saluja

Damon R Asher

Rifat Sharif

The present invention provides a snare molecules comprising an attachment moiety (which facilitates attachment of a receptor to a cell) and a receptor for a toxic pathogenic or infectious agent, e.g., a virus. Methods of producing such snare molecules and their therapeutic and/or prophylactic uses are also provided by the present invention.

Snares for pathogenic or infectious agents and uses related thereto

This disclosure provides compositions, kits, and methods useful for treating or preventing viral and bacterial infection and reducing or preventing the effects of toxins. The methods comprise administering to a subject an effective amount of a liposomal composition.

Multivalent liposome formulations

The present invention is directed to methods, kits, and uses of inhibitors of LCMV mediated NF-&#x3ba;B activation to treat viral infections and inflammatory conditions.

Compounds for modulating TLR2

Toll-like receptor 2 (TLR2) has been found to mediate certain effects of HSV infection, particularly in neonates. Compounds that decrease TLR2 expression or activity are useful for ameliorating such deleterious effects.

Modulation of HSV infection

The present invention provides methods of identifying candidate therapeutic agents for use in the treatment of acute pancreatitis.

Pancreatitis

It has been found that Toll-like receptor 1 and Toll-like receptor 2 (TLR2) physically interact. Antibodies that specifically bind to TLR2 and selectively inhibit induction of cytokines are also described. The invention relates to specific antibodies that selectively bind to TLR2, and to methods of identifying compounds that selectively interfere with signaling through TLR1/TLR2 complexes.

Antibodies to toll-like receptor-2

The present invention is directed, at least in part, to mice which express exogenous complement receptor type 1 (CR1) on red blood cells. The invention also pertains to genetic constructs encoding heterologous CR1 for expression on red blood cells. Methods of using the transgenic animals of the invention to identify and/or evaluate compositions that can reduce the concentration of an agent, e.g., a biologic agent, in the serum, circulation and/or tissues of a subject are also provided.

Growing community of inventors

Sudbury, MA, United States of America

Robert W Finberg